Home › Research › Costs and economics
Utilization and Lifetime Costs of Formal Care for Alzheimer's Disease Dementia in Sweden
Xia X, Eriksdotter M, Clark A, Brogaard NJ, Gundgaard J, Polavieja P, Skajaa N, Zetterberg H, Kern S, Skillbäck TB, Jönsson L. PharmacoEconomics, 2026-04-01
Topic: Risk, prevention and care in population studies
Plain-language summary
Introduction The study aimed to estimate the utilization and lifetime costs of formal care for individuals with Alzheimer's disease (AD) dementia in Sweden. Methods We used longitudinal data from 20,366 individuals (mean age: 78.54 years) diagnosed with AD dementia from the Swedish Register of Cognitive/Dementia Disorders linked to other registers to derive data on formal care utilization, including inpatient and outpatient specialist care, prescribed drugs, and social care. We estimated formal care utilization across AD dementia stages defined by the Mini-Mental State Examination and the lifetime formal care costs (in 2023 Swedish krona, SEK) in patients with AD dementia using the Zhao and Tian estimator, which uses the inverse probability weighting technique to account for censoring due to loss to follow-up. The estimates of lifetime costs were compared with those of controls matched to patients with AD dementia by birth year, sex, and region of residence at the time of diagnosis. Results The number of outpatient specialist visits decreased as AD severity increased, while the number of drug prescriptions and social care utilization increased with advancing AD stages. The estimated lifetime costs of formal care for AD dementia were 2,440,000 SEK (€212,174; $US230,189; 95% CI 2,088,000-2,793,000 SEK), compared with 510,000 SEK (€44,348; $US48,113; 95% CI 482,000-539,000 SEK) for matched controls. Conclusions This study estimated the utilization and lifetime costs of formal care for AD dementia using longitudinal register data. These findings will provide inputs for future economic evaluations of treatments and preventive interventions for AD dementia.
What this study adds
Evidence grade: High
This is a follow-up (cohort) study of 20,366 participants. This register-based study estimated that lifetime formal care costs for people with Alzheimer's disease dementia in Sweden were about 2,440,000 SEK, compared with 510,000 SEK for matched controls, with drug prescriptions and social care use rising as disease severity increased. Reported effect size: Lifetime formal-care cost 2,440,000 SEK vs 510,000 SEK for matched controls.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Xia, X., Eriksdotter, M., Clark, A., Brogaard, N. J., Gundgaard, J., Polavieja, P., et al. (2026). Utilization and Lifetime Costs of Formal Care for Alzheimer's Disease Dementia in Sweden. PharmacoEconomics. https://doi.org/10.1007/s40273-026-01612-5
Vancouver
Xia X, Eriksdotter M, Clark A, Brogaard NJ, Gundgaard J, Polavieja P, et al. Utilization and Lifetime Costs of Formal Care for Alzheimer's Disease Dementia in Sweden. PharmacoEconomics. 2026. doi:10.1007/s40273-026-01612-5. PMID: 41920501.
BibTeX
@article{xia2026-41920501,
author = {Xia, X. and Eriksdotter, M. and Clark, A. and Brogaard, N. J. and Gundgaard, J. and Polavieja, P. and Skajaa, N. and Zetterberg, H. and Kern, S. and Skillbäck, T. B. and Jönsson, L.},
title = {{Utilization and Lifetime Costs of Formal Care for Alzheimer's Disease Dementia in Sweden}},
journal = {PharmacoEconomics},
year = {2026},
doi = {10.1007/s40273-026-01612-5},
pmid = {41920501},
url = {https://doi.org/10.1007/s40273-026-01612-5}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 11 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- The estimates of lifetime costs were compared with those of controls matched to patients with AD dementia by birth year, sex, and region of residence at the time of diagnosis.
- Results The number of outpatient specialist visits decreased as AD severity increased, while the number of drug prescriptions and social care utilization increased with advancing AD stages.
- The estimated lifetime costs of formal care for AD dementia were 2,440,000 SEK (€212,174; $US230,189; 95% CI 2,088,000-2,793,000 SEK), compared with 510,000 SEK (€44,348; $US48,113; 95% CI 482,000-539,000 SEK) for matched controls.
- These findings will provide inputs for future economic evaluations of treatments and preventive interventions for AD dementia.
Why it matters
This register-based study estimated that lifetime formal care costs for people with Alzheimer's disease dementia in Sweden were about 2,440,000 SEK, compared with 510,000 SEK for matched controls, with drug prescriptions and social care use rising as disease severity increased. It describes the cost of care over the disease course and does not test any treatment, cure or prevention.
New to this subject? Start with our plain-English guide: Costs & economics →
Study details
- Study designcohort
- Participants20,366
- Effect sizeLifetime formal-care cost 2,440,000 SEK vs 510,000 SEK for matched controls
- Evidence strengthHigh
Limitations
Primary care visits were not included owing to lack of data, likely underestimating costs; the eight-year window may not capture the full interval from diagnosis to death; truncating controls' follow-up to match cases may have overestimated the cost difference; the MCI stage was not considered because of insufficient data.
How this study scored 56/100
Published in a peer-reviewed journal, and it is a cohort study following people over time. Scored zero for randomized / blinded because the record does not state it. We have no data on free to read, so that was left out: it earned 55 of the 98 points we could judge it on, which is 56 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (PharmacoEconomics) |
| Journal's citation record | 2 / 4 | PharmacoEconomics: journal h-index 153 (OpenAlex, 2026-10-29) |
| Study design | 7 / 12 | A cohort study following people over time |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 4 / 4 | 20,366 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Linus Jönsson: h-index 55 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University College London: institution h-index 2,029 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 11 institution(s) in 5 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41920501) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 55 / 98 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 55 of the 98 points we could judge it on is 56 out of 100. |
| Total | 56 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Costs and economics from nearby years
Also tagged “prevalence”
1,225 studies in the library carry the topic tag “prevalence”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,225 tagged studies.